Cancer Molecular Genetics Prgm

癌症分子遗传学项目

• 批准号: 9365072
• 负责人: GORDON D GINDER
• 金额: $ 7.05万
• 依托单位: VIRGINIA COMMONWEALTH UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-05-01 至 2017-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9365072
• 关键词: Achievement; Behavior; Cancer Center; Cancer Center Support Grant; Cancerous; Cell Death; Cells; Cellular biology; Clinic; Collaborations; Defect; Dentistry; Development; Diagnosis; Epigenetic Process; Event; Funding; Funding Agency; Gene Expression; Genes; Genetic; Genetic Programming; Goals; Grant; Instruction; Knowledge; Laboratories; Malignant Neoplasms; Molecular; Molecular Genetics; Mutation; Normal Cell; Peer Review; Property; Public Health; Publications; Research; Research Personnel; Role; Signal Transduction; Therapeutic; United States National Institutes of Health; Universities; Virginia; base; cancer cell; cancer therapy; improved; innovation; interest; medical schools; member; multidisciplinary; next generation; programs; therapy development

The Cancer Molecular Genetics (CMG) program is a newly formed program resulting from the restructuring of the former Cancer Cell Biology program into two smaller and more cohesive programs [the other being the Cancer Cell Signaling (CCS) program]. Members of this program share a common interest in the genetic and epigenetic changes that underlie the molecular and cellular events contributing to cancer development and progression. The primary scientific goals of the CMG program are to define the genes contributing to cancer development and progression, to identify the genetic and epigenetic mechanisms regulating expression of these genes in normal and cancer cells, to determine their role in governing the properties and behaviors of cancer cells, to identify mechanisms by which identified defects in cancer cells can be exploited to selectively induce cancer cell death, and ultimately to use this knowledge to develop innovative approaches for the treatment of currently intractable cancers. The CMG program consists of a multidisciplinary group of 22 investigators from eight academic departments from the Schools of Medicine and Dentistry. The CMG program has a funding base of over $5.4 million dollars in annual direct support, of which more than $4.2 million is from NIH or other peer-reviewed funding sources. Members of the CMG program have multiple well-established and productive collaborations, both within the program and with members of other Virginia Commonwealth University (VCU) Massey Cancer Center (MCC) programs, which have resulted in jointly funded research initiatives and high-impact publications in recent years. Greater than three-quarters of the 189 publications from CMG program members in the past grant period resulted from collaborations with other MCC members. 52% of which involved intra-programmatic, 48% involved inter-programmatic collaborations, and 2 1% involved both intra and inter- programmatic collaborations. The central goal of the CMG program is to facilitate achievement of the overarching goal of the MCC, namely to move laboratory advances into the clinic for improved diagnosis and therapy of cancer. By gaining a better understanding of the underlying molecular basis of cancer development and progression, it will be possible to develop the next generation of cancer therapeutics.

癌症分子遗传学（CMG）程序是由重组产生的新形成的程序 以前的癌细胞生物学计划分为两个较小且更具凝聚力的计划[另一个是 癌细胞信号传导（CCS）程序]。该计划的成员在遗传和 表观遗传学变化是有助于癌症发展和的分子和细胞事件的基础 进展。 CMG计划的主要科学目标是定义导致癌症的基因 发展和进展，以确定调节表达的遗传和表观遗传机制 这些基因在正常和癌细胞中，以确定它们在管理的特性和行为中的作用 癌细胞，以确定可以利用癌细胞中发现缺陷的机制 诱导癌细胞死亡，并最终使用这些知识来开发创新方法 目前棘手的癌症的治疗。 CMG计划由来自八个学术部门的22位调查人员组成的多学科小组 来自医学和牙科学校。 CMG计划的资金基础超过540万美元 年度直接支持的美元，其中超过420万美元来自NIH或其他同行评审的资金 来源。 CMG计划的成员有多次建立良好且富有成效的合作 在该计划中以及其他弗吉尼亚联邦大学（VCU）的成员Massey Cancer 中心（MCC）计划，已产生共同资助的研究计划和高影响力 近年来出版物。 CMG计划中的189个出版物中的四分之三大于四分之三 在过去的赠款期间，成员是由与其他MCC成员的合作产生的。其中52％ 涉及涉及的截面，有48％的涉及程序间合作，而2 1％涉及内部和 跨程序合作。 CMG计划的核心目标是促进实现MCC的总体目标 将实验室进步转移到诊所，以改善癌症的诊断和治疗。通过更好 了解癌症发展和进展的基本分子基础，这是可能的 发展下一代癌症治疗剂。